Advanced

Topical nasal steroid treatment does not improve CPAP compliance in unselected patients with OSAS

Strobel, Werner; Schlageter, Manuel; Andersson, Morgan LU ; Miedinger, David; Chhajed, Prashant N.; Tamm, Michael and Leuppi, Joerg D. (2011) In Respiratory Medicine 105(2). p.310-315
Abstract
Background: Continuous positive airways pressure (CPAP) for treatment of obstructive sleep apnea (OSA) can produce troublesome nasal symptoms (i.e. congestion, rhinorrhea) that may reduce the compliance of CPAP. Topical nasal steroids are often prescribed to reduce these side effects, although scientific data are scarce supporting any benefits of this treatment for CPAP-induced nasal side effects. Objective: To study whether a topical nasal steroid can reduce CPAP-induced nasal symptoms and improve CPAP adherence during the initial phase of OSA treatment. Methods: A randomized, double-blinded, placebo-controlled study with fluticasone propionate 100 mu g/nasal cavity twice daily Treatment was started 10 days prior to and continued... (More)
Background: Continuous positive airways pressure (CPAP) for treatment of obstructive sleep apnea (OSA) can produce troublesome nasal symptoms (i.e. congestion, rhinorrhea) that may reduce the compliance of CPAP. Topical nasal steroids are often prescribed to reduce these side effects, although scientific data are scarce supporting any benefits of this treatment for CPAP-induced nasal side effects. Objective: To study whether a topical nasal steroid can reduce CPAP-induced nasal symptoms and improve CPAP adherence during the initial phase of OSA treatment. Methods: A randomized, double-blinded, placebo-controlled study with fluticasone propionate 100 mu g/nasal cavity twice daily Treatment was started 10 days prior to and continued throughout the first 4 weeks of CPAP. 63 patients who were selected for CPAP treatment participated. Nasal symptoms were recorded, nasal patency was assessed and lung function was measured with a peak flow meter. The patients' adherence to CPAP was recorded by the CPAP device. Results: Total nasal symptoms increased from baseline to 4 wks after CPAP use for both nasal treatments (p < 0.05). No differences in total nasal symptoms between treatments were seen (p = 1), and no differences in nasal peak flow values after treatment were seen (p = 0.11). Moreover, there were no differences in CPAP use between the treatments. Conclusion: Fluticasone propionate as a nasal topical steroid does not reduce CPAP-induced unwanted nasal side effects, and has no beneficial effect on CPAP compliance during the first four weeks of treatment in unselected patients with OSAS. (C) 2010 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Allergy, Apnea, Sleep, Steroid
in
Respiratory Medicine
volume
105
issue
2
pages
310 - 315
publisher
Elsevier
external identifiers
  • wos:000287116100021
  • scopus:78651404260
ISSN
1532-3064
DOI
10.1016/j.rmed.2010.10.003
language
English
LU publication?
yes
id
a77f9226-51c6-44c9-aa3c-29affa972d03 (old id 1870063)
date added to LUP
2011-04-04 08:27:23
date last changed
2017-08-27 04:52:57
@article{a77f9226-51c6-44c9-aa3c-29affa972d03,
  abstract     = {Background: Continuous positive airways pressure (CPAP) for treatment of obstructive sleep apnea (OSA) can produce troublesome nasal symptoms (i.e. congestion, rhinorrhea) that may reduce the compliance of CPAP. Topical nasal steroids are often prescribed to reduce these side effects, although scientific data are scarce supporting any benefits of this treatment for CPAP-induced nasal side effects. Objective: To study whether a topical nasal steroid can reduce CPAP-induced nasal symptoms and improve CPAP adherence during the initial phase of OSA treatment. Methods: A randomized, double-blinded, placebo-controlled study with fluticasone propionate 100 mu g/nasal cavity twice daily Treatment was started 10 days prior to and continued throughout the first 4 weeks of CPAP. 63 patients who were selected for CPAP treatment participated. Nasal symptoms were recorded, nasal patency was assessed and lung function was measured with a peak flow meter. The patients' adherence to CPAP was recorded by the CPAP device. Results: Total nasal symptoms increased from baseline to 4 wks after CPAP use for both nasal treatments (p &lt; 0.05). No differences in total nasal symptoms between treatments were seen (p = 1), and no differences in nasal peak flow values after treatment were seen (p = 0.11). Moreover, there were no differences in CPAP use between the treatments. Conclusion: Fluticasone propionate as a nasal topical steroid does not reduce CPAP-induced unwanted nasal side effects, and has no beneficial effect on CPAP compliance during the first four weeks of treatment in unselected patients with OSAS. (C) 2010 Elsevier Ltd. All rights reserved.},
  author       = {Strobel, Werner and Schlageter, Manuel and Andersson, Morgan and Miedinger, David and Chhajed, Prashant N. and Tamm, Michael and Leuppi, Joerg D.},
  issn         = {1532-3064},
  keyword      = {Allergy,Apnea,Sleep,Steroid},
  language     = {eng},
  number       = {2},
  pages        = {310--315},
  publisher    = {Elsevier},
  series       = {Respiratory Medicine},
  title        = {Topical nasal steroid treatment does not improve CPAP compliance in unselected patients with OSAS},
  url          = {http://dx.doi.org/10.1016/j.rmed.2010.10.003},
  volume       = {105},
  year         = {2011},
}